基于Zigbee技术的高压开关触点温度在线监测技术

高压开关柜是电力系统中极为重要的组成结构,对于电力系统的运行起到了通断、控制、保护的作用,避免了系统受到各种故障的影响而出现损坏。为了保持高压开关柜性能的发挥,对其触点温度实施监测控制可及时观察到可能发生的故障,采取措施后把故障损失控制在最小。文章分析了ZigBee技术在高压开关柜触点温度监测中的运用。     

煤矿机电设备的状态监测与故障诊断

煤矿机电设备状态的监测与故障诊断可以有效的缓解此问题产生的频率、程度、及设备的故障率,可以增大煤炭企业的安全生产,减少机电事故。本文介绍了煤矿机电设备作业的特点、维修及对设备故障的提前预防的意义,特别强调了机电设备运行状态监测及故障诊断在煤矿安全生产中的应用、发展及不足之处。     

基于物联网技术的冷链物流制冷监控系统

对物联网技术进行了分析,并从物联网技术的角度对冷链物流的制冷系统进行了研究,对其系统设计方案以及涉及的关键技术等进行了介绍。     

污染场地现场调查与监测模式研究

污染场地调查与监测是场地环境管理、风险评估与修复治理的重要环节。文章介绍了国内外污染场地调查评估的阶段划分与勘察技术,分析了国内场地调查工作模式以及环境监测工作程序,提出了现有的常用监测技术,并总结了目前国内污染场地勘察与监测的研究现状。     

Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective

Aims/hypothesis:

Continuous subcutaneous insulin infusion (CSII) is an important treatment option for type 1 diabetes patients unable to achieve adequate glycemic control with multiple daily injections (MDI). Combining CSII with continuous glucose monitoring (CGM) in sensor-augmented pump therapy (SAP) with a low glucose-suspend (LGS) feature may further improve glycemic control and reduce the frequency of hypoglycemia. A cost-effectiveness analysis of SAP?+?LGS vs CSII plus self-monitoring of blood glucose (SMBG) was performed to determine the health economic benefits of SAP?+?LGS in type 1 diabetes patients using CSII in the UK.

Methods:

Cost-effectiveness analysis was performed using the CORE diabetes model. Treatment effects were sourced from the literature, where SAP?+?LGS was associated with a projected HbA_1c reduction of ?1.49% vs ?0.62% for CSII, and a reduced frequency of severe hypoglycemia. The time horizon was that of patient lifetimes; future costs and clinical outcomes were discounted at 3.5% and 1.5% per annum, respectively.

Results:

Projected outcomes showed that SAP?+?LGS was associated with higher mean quality-adjusted life expectancy (17.9 vs 14.9 quality-adjusted life years [QALYs], SAP?+?LGS vs CSII), and higher life expectancy (23.8 vs 21.9 years), but higher mean lifetime direct costs (GBP 125,559 vs GBP 88,991), leading to an incremental cost-effectiveness ratio (ICER) of GBP 12,233 per QALY gained for SAP?+?LGS vs CSII. Findings of the base-case analysis remained robust in sensitivity analyses.

Conclusions/interpretation:

For UK-based type 1 diabetes patients with poor glycemic control, the use of SAP?+?LGS is likely to be cost-effective compared with CSII plus SMBG.